Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05205954 · ClinicalTrials.gov registry record · NA

HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease

A NA study of Cirrhosis and End Stage Liver DIsease, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
2
Study locations

NCT05205954 is a NA study of Cirrhosis and End Stage Liver DIsease that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 30 participants, below the 90,408-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05205954, a NA study of Cirrhosis and End Stage Liver DIsease, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
2
Study locations

Study Summary

This research study is evaluating a program that entails a healthcare at home intervention for people with advanced liver disease.

Interventions

  • BEHAVIORAL Hepatology Home Hospital

Study Locations (2)

Massachusetts

  • Massachusetts General Hospital - Boston
  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-07-21
Est. Completion 2026-12-31
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT05205954

The ClinicalTrials.gov registry entry for NCT05205954 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90,408-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Cirrhosis appearing as the primary indexed condition, and to 1 intervention - of which Hepatology Home Hospital is the first listed.

NCT05205954 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05205954 about?

NCT05205954 is a clinical study titled "HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease". This research study is evaluating a program that entails a healthcare at home intervention for people with advanced liver disease.

What is the current status of trial NCT05205954?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-07-21. Estimated completion is 2026-12-31.

What conditions does trial NCT05205954 study?

This clinical trial studies the following conditions: Cirrhosis, End Stage Liver DIsease, Liver Cirrhosis, Liver Disease Chronic.

What interventions are being tested in trial NCT05205954?

The interventions under investigation include: Hepatology Home Hospital (BEHAVIORAL).

Who is sponsoring clinical trial NCT05205954?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05205954 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cirrhosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.